IL33 and Miyoshi myopathy: In vitro and in vivo experiments demonstrated that IL‐33 and BTZ synergistically exerted anti‐MM efficacy via stimulating excessive accumulation of ROS, thereby attenuating NF‐κB signal and suppressing stemness properties of MM cells.